{
  "ticker": "OIL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960775",
  "id": "02960775",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250623",
  "time": "0841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06kzw4z8w4w2yy.pdf",
  "summary": "### Summary of Material Information:  \n**Announcement Type: Strategic Collaboration Agreement**  \n\n- **Exclusive Collaboration** signed with US-based Long Grove Pharmaceuticals for clinical studies and trials.  \n- **Key Objective**: Combine Optiscan\u2019s InVue\u00ae imaging device with Long Grove\u2019s AK-FLOUR\u00ae contrast agent to explore new clinical applications (initially breast surgery).  \n- **Regulatory Impact**: Data to support Optiscan\u2019s FDA submissions for InVue\u00ae; potential expedited approvals via Long Grove\u2019s existing drug data (CMC).  \n- **Term**: 5-year agreement, with potential for expanded applications (gastrointestinal, robotic surgery).  \n- **Commercial Implication**: Strengthens Optiscan\u2019s foothold in the U.S. market and supports pipeline growth.  \n\n**No capital raising, financial figures, or trading halt details disclosed.**",
  "usage": {
    "prompt_tokens": 2631,
    "completion_tokens": 182,
    "total_tokens": 2813,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T22:47:17.237908"
}